CorMedix (CRMD) Intangibles (2019 - 2026)
CorMedix (CRMD) posted Intangibles of $379.1 million for Q4 2025, down 3.76% sequentially from $393.9 million in Q3 2025, and up 18853.6% YoY from N/an in Q4 2024.
CorMedix (CRMD) Intangibles (2019 - 2026) Analysis & Trends
CorMedix has reported Intangibles for 4 years, with the latest figure at $379.1 million in Q4 2025.
- Quarterly Intangibles rose 18853.6% year-over-year to $379.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $379.1 million (up 18853.6% YoY) and the FY2025 annual result came in at $379.1 million, up 18853.6% from the prior year.
- Intangibles declined to $379.1 million in Q4 2025 per CRMD's latest filing, from $393.9 million in the prior quarter.
- Over five years, Intangibles peaked at $393.9 million in Q3 2025 and troughed at $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 358.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358.47 Mn |
| Dec 31, 2025 | 379.07 Mn |
| Sep 30, 2025 | 393.90 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2020 | 372,454.00 |
| Jun 30, 2020 | 296,574.00 |
| Dec 31, 2019 | 10,081.00 |